[1] YAMADA S， SUGAHARA K. Potential therapeutic application of chondroitin sulfate/dermatan sulfate[J]. Curr Drug Discov Technol， 2008， 5(4)： 289-301.
[2] MALAVAKI C， MIZUMOTO S， KARAMANOS N， et al. Recent advances in the structural study of functional chondroitin sulfate and dermatan sulfate in health and disease[J]. Connect Tissue Res， 2008， 49(3)：133-139.
[3] VOLPI N. Analytical aspects of pharmaceutical grade chondroitin sulfates[J]. J Pharm Sci， 2007， 96(12)： 3168-3180.
[4] WINKELMAYER W C， WAIKAR S S， MOGUN H， et al. Nonselective and cyclooxygenase- 2-selective NSAIDs and acute kidney injury[J]. Am J Med， 2008， 121(12)：1092-1098.
[5] HOCHBERG M C， CLEGG D O. Potential effects of chondroitin sulfate on joint swelling： a GAIT report[J]. Osteoarthritis Cartilage， 2008， 16(suppl 3)： 22-24.
[6] MCCARTHY G， O'DONOVAN J， JONES B， et al. Randomised double-blind， positive- controlled trial to assess the efficacy of glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis[J]. Vet J， 2007， 174(1)： 54-61.
[7] HOCHBERG M C. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis： an updated meta-analysis of randomized placebo-controlled trials of 2-year duration[J]. Osteoarthritis Cartilage， 2010， 18(suppl 1)： 28-31.
[8] MONFORT J， MARTEL-PELLETIER J， PELLETIER J P. Chondroitin sulphate for symptomatic osteoarthritis： critical appraisal of meta-analyses[J]. Curr Med Res Opin， 2008， 24(5)： 1303-1308.
[9] MICHEL B A， STUCKI G， FREY D， et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee： a randomized， controlled trial[J]. Arthritis Rheum， 2005， 52(3)： 779-786.
[10] UEBELHART D， MALAISE M， MARCOLONGO R， et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate： a one-year， randomized， double-blind， multicenter study versus placebo[J]. Osteoarthritis Cartilage， 2004，12(4)： 269-276.
[11] UEBELHART D， THONAR E J， DELMAS P D， et al. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis： a pilot study[J]. Osteoarthritis Cartilage， 1998， 6 (suppl A)： 39-46.
[12] VOLPI N. Chondroitin Sultate: Structure, Role and Pharmacological Activity[M]. Amsterdam: academic Press, 2006： 475-488.
[13] VERBRUGGEN G， GOEMAERE S， VEYS E M. Chondroitin sulfate： S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA[J]. Osteoarthritis Cartilage， 1998， 6 (suppl A)： 37-38.
[14] VERBRUGGEN G， GOEMAERE S， VEYS E M. Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs[J]. Clin Rheumatol， 2002， 21(3)： 231-243.
[15] JORDAN K M， ARDEN N K， DOHERTY M， et al. EULAR Recommendations 2003： an evidence based approach to the management of knee osteoarthritis： report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)[J]. Ann Rheum Dis， 2003， 62(12)： 1145-1155.
[16] CLEGG D O， REDA D J， HARRIS C L， et al. Glucosamine， chondroitin sulfate， and the two in combination for painful knee osteoarthritis[J]. N Engl J Med， 2006， 354(8)： 795-808.
[17] REICHENBACH S， STERCHI R， SCHERER M， et al. Meta-analysis： chondroitin for osteoarthritis of the knee or hip[J]. Ann Intern Med， 2007， 146(8)： 580-590.
[18] VOLPI N. Chondroitin Sulfate： Structure， Role and Pharmacological Activity[M]. Amsterdam： Academic Press， 2006： 403.
[19] RONCA G, CONTE A. Metabolic fate of partially depolymerized shark chondroitin sulfate in man[J]. Int J Clin Pharmacol Res， 1993, 13（Suppl）：27-34.
[20] CONTE A, PALMIERI L, SEGNINI D, et al. Metabolic fate of partially depolimerized chondroitin sulfate administered to the rat[J]. Drugs Exp Clin Res， 1991， 17（1）：27-33.
[21] SAKAI S， ONOSE J， NAKAMURA H， et al. Pretreatment procedure for the microdetermination of chondroitin sulfate in plasma and urine[J]. Anal Biochem， 2002， 302(2)：169-174.
[22] WRENSHALL L E， STEVENS R B， CERRA F B， et al. Modulation of macrophage and B cell function by glycosaminoglycans[J]. J Leukoc Biol， 1999， 66(3)： 391-400.
[23] PECCHI E， PRIAM S， MLADENOVIC Z， et al. A potential role of chondroitin sulfate on bone in osteoarthritis： inhibition of prostaglandin E(2) and matrix metalloproteinases synthesis in interleukin-1β-stimulated osteoblasts[J]. Osteoarthritis Cartilage， 2012， 20（2）：127-135.
[24] AIGNER T， SOEDER S， HAAG J. IL-1beta and BMPs-interactive players of cartilage matrix degradation and regeneration[J]. Eur Cell Mater， 2006，12： 49-56.
[25] SAWITZKE A D， SHI H， FINCO M F， et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis： a report from the glucosamine/chondroitin arthritis intervention trial[J]. Arthritis Rheum， 2008， 58(10)： 3183-3191.
[26] MESSIER S P， MIHALKO S， LOESER R F， et al. Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis： a preliminary study[J]. Osteoarthritis Cartilage， 2007， 15(11)： 1256-1266.
[27] GABAY C， MEDINGER-SADOWSKI C， GASCON D， et al. Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis： a randomized， double-blind， placebo-controlled clinical trial at a single center[J]. Arthritis Rheum， 2011， 63(11)： 3383-3391.
[28] WILDI L M， RAYNAULD J P， MARTEL-PELLETIER J， et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy： a randomised， double-blind， placebo-controlled pilot study using MRI[J]. Ann Rheum Dis， 2011， 70(6)：982-989.